CANCEROMICSProject reference: 2728
Funded under: FP6-MOBILITY
Total cost:Not available
EU contribution:EUR 1 806 477
Call for proposal:FP6-2002-MOBILITY-8
Funding scheme:EXT - Marie Curie actions-Grants for Excellent Teams
This proposal is focussing on the development and application of novel microarray technologies at the molecular, cellular and patient level, and their application in cancer research and therapy development.
The research program will be focussing on the development of new high-throughput technologies that have broad application potential in translational genomics. The biological focus driving our technology development is the identification of causative gene targets in cancer cells, which we believe will for m a basis for effective development of novel anti-cancer agents.
The goals of the three projects are:
- Develop novel molecular biochip strategies (such as NMD and CGH microarrays) for identification of genes that are targets of genomic alterations in cancer,
- Develop cell-based, functional microarrays for identification and validation of critical gene targets in living cells,
- Develop clinical tumour tissue lysate arrays for automated, large-scale immunoprofiling of tumours to characterize diagnostic and therapeutic antibodies.
The research will take place at the Medical Biotechnology group of the Technical Research Centre of Finland (VTT), a new research program launched in collaboration with VTT and the University of Turku in Finland. The research component supported will establish a strong international network, and will facilitate scientist exchange.